According to a survey by the China Investment Advisory Network, the market for monoclonal antibodies and insulin-like drugs will grow rapidly and is expected to account for 46% of the total biotech market in 2018. In 2016, the global bio-similar drug market is estimated at about 4.2 billion US$. Due to the high threshold of market access, biosimilar drugs are expected to maintain a good market competitiveness, and their price will generally only decline by 10% -30%, whereas prizes of chemical generic drugs are expected to decline over 50 %.

China Bio news release, August 4, 2017